Oppenheimer set a $14.00 price objective on TherapeuticsMD (NASDAQ:TXMD) in a report issued on Wednesday morning. The firm currently has a buy rating on the stock.

A number of other research firms have also issued reports on TXMD. BidaskClub upgraded TherapeuticsMD from a sell rating to a hold rating in a report on Friday, June 8th. JPMorgan Chase & Co. assumed coverage on TherapeuticsMD in a report on Friday, June 15th. They issued an overweight rating and a $11.00 target price for the company. ValuEngine upgraded TherapeuticsMD from a hold rating to a buy rating in a report on Friday, September 21st. Zacks Investment Research upgraded TherapeuticsMD from a sell rating to a hold rating in a report on Saturday, August 25th. Finally, Cantor Fitzgerald set a $26.00 target price on TherapeuticsMD and gave the company a buy rating in a report on Monday, July 30th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. TherapeuticsMD has a consensus rating of Buy and a consensus target price of $15.40.

TXMD opened at $6.71 on Wednesday. TherapeuticsMD has a 52 week low of $4.34 and a 52 week high of $7.66. The firm has a market cap of $1.58 billion, a PE ratio of -18.14 and a beta of 1.55. The company has a quick ratio of 7.79, a current ratio of 7.88 and a debt-to-equity ratio of 0.94.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The firm had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $4.23 million. During the same quarter in the prior year, the business earned ($0.10) earnings per share. The company’s quarterly revenue was down 11.6% on a year-over-year basis. equities research analysts predict that TherapeuticsMD will post -0.63 earnings per share for the current fiscal year.

In other TherapeuticsMD news, Director Brian Bernick sold 182,800 shares of TherapeuticsMD stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $6.30, for a total transaction of $1,151,640.00. Following the completion of the sale, the director now directly owns 242,000 shares of the company’s stock, valued at approximately $1,524,600. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert G. Finizio sold 184,000 shares of TherapeuticsMD stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $6.63, for a total value of $1,219,920.00. Following the sale, the chief executive officer now directly owns 18,485,559 shares of the company’s stock, valued at $122,559,256.17. The disclosure for this sale can be found here. Over the last quarter, insiders sold 800,800 shares of company stock valued at $5,044,720. 22.85% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fox Run Management L.L.C. purchased a new stake in TherapeuticsMD during the 2nd quarter worth about $121,000. Xact Kapitalforvaltning AB lifted its holdings in TherapeuticsMD by 96.3% during the 1st quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock worth $155,000 after buying an additional 15,600 shares during the last quarter. Affiance Financial LLC purchased a new stake in TherapeuticsMD during the 2nd quarter worth about $156,000. Barclays PLC lifted its holdings in TherapeuticsMD by 33,787.3% during the 1st quarter. Barclays PLC now owns 37,276 shares of the company’s stock worth $182,000 after buying an additional 37,166 shares during the last quarter. Finally, Twin Focus Capital Partners LLC purchased a new stake in TherapeuticsMD during the 2nd quarter worth about $187,000. 66.14% of the stock is owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Read More: What Is An Exchange-Traded Fund (ETF)?

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.